Skip to main content
Leukemia
Effect of Early Blood Counts on Response and Overall SurvEffect of Early Blood Counts on Response and Overall Survival Following Glasdegib + LDAC in Newly Diagnosed AMLival Following Glasdegib + LDAC in Newly Diagnosed AML
Read More
Leukemia, Venetoclax
Venetoclax plus Standard Intensive AML Induction/Consolidation with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML
Read More
Leukemia
Clinical Outcomes for Treatment-Naïve Patients with AML Ineligible for Intensive Chemotherapy Receiving Azacitidine or Decitabine
Read More
Leukemia
SAL-DaunoDouble Trial Interim Analysis: Single versus Double Induction with 7+3 for Patients with Newly Diagnosed AML
Read More
Leukemia
Prognostic Significance of Concomitant Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML
Read More
Leukemia, Venetoclax
Decitabine + Venetoclax versus Intensive Chemotherapy for Patients with Relapsed/Refractory AML: A Propensity Score–Matched Analysis
Read More
Leukemia
Escalated Dosing Schedules of CC-486 Effective for Patients Experiencing First AML Low Blast Count Relapse
Read More
Leukemia
Gilteritinib + Azacitidine or Azacitidine Alone in Patients with Newly Diagnosed, FLT3-Mutated Acute Myeloid Leukemia
Read More
Leukemia, Venetoclax
Comparative Effectiveness of Glasdegib or Venetoclax in Combination with Low-Dose Cytarabine Using Simulated Treatment Comparisons
Read More
Leukemia, Venetoclax
Phase 1b/2 Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies
Read More
Page 123 of 199
Results 1221 - 1230 of 1986